Background
==========

The prevalence of obesity is rising globally, independent of ethnicity, race and age, and is associated with increased mortality and morbidity \[[@B1],[@B2]\]. Obesity rates in Scandinavia represent no exception \[[@B3]-[@B5]\]. Importantly, the prevalence of morbid obesity, defined as BMI ≥ 40.0 kg/m^2^or BMI 35.0 -39.9 kg/m^2^and an obesity-related comorbidity, is increasing at an even steeper rate \[[@B6]\]. Two percent of the Norwegian population\[[@B7]\] can be classified as morbidly obese.

Several lines of evidence indicate that the distribution of fat is a major determinant of cardiovascular risk in both normalweight, overweight and moderately obese subjects \[[@B8]-[@B10]\], although measures of general obesity and physiological differences between genders must also be considered \[[@B11]-[@B13]\]. Only a few studies in morbidly obese subjects have compared the effect of overall and central obesity on cardiovascular risks and the results have been inconsistent both within, and between genders \[[@B14]-[@B16]\]. Other studies have reported an increased risk of death in persons with BMI \> 35 kg/m^2^\[[@B17],[@B18]\], but the increase in mortality has been linked to comorbidities rather than the obesity \[[@B19]\] suggesting that morbid obesity without comorbidities is not a cardiovascular risk factor regardless of fat distribution.

Nevertheless, obesity is a major modifiable risk factor for coronary artery disease (CAD) that imparts a degree of cardiovascular risk similar to that associated with hypertension, hyperlipidemia, smoking and sedentary lifestyle \[[@B20]\]. Accordingly, it seems to be a paradox that the increasing obesity rates coincide with a decreased risk of cardiovascular death \[[@B21]\]. The latency time for developing cardiovascular disorders may, however, be several decades \[[@B22],[@B23]\]. Thus, early risk markers are needed to identify obese subjects at risk.

Arterial stiffness assessed by pulse wave velocity (PWV) is an independent predictor of cardiovascular morbidity and mortality \[[@B24],[@B25]\], and PWV is increasingly recognized as a valid surrogate endpoint of cardiovascular disease \[[@B26],[@B27]\].

The main objective of this study was to examine the possible relationship between various measures of body composition and arterial stiffness PWV. We hypothesized that in morbidly obese subjects abdominal obesity is a better predictor of aortic stiffness than general obesity.

Methods
=======

Study design
------------

This is an analysis of cross-sectional baseline data from a non-randomized clinical trial comparing the effects of a comprehensive lifestyle modification program and bariatric surgery on arterial stiffness in morbidly obese patients. (<http://ClinicalTrials.gov> Identifier NCT00626964).

Setting
-------

The study was performed at a tertiary care centre (the Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg, Norway) between February 2008 and January 2010. Before inclusion patients were either assigned to a comprehensive lifestyle modification program at the Hospital for Rehabilitation, Stavern, or to bariatric surgery at the Morbid Obesity Centre.

Participants and study size
---------------------------

All participants were recruited from our tertiary care centre and had to reside within 100 km of either the hospital for rehabilitation or our clinic. The patients in the intensive lifestyle intervention group were all selected from patients that had signed up for participation in a standardized health promoting and weight reductive program at the hospital for rehabilitation. Participants in the surgery group were selected from patients preparing for bariatric surgery at our hospital. The decision regarding the type of intervention was made prior to the inclusion to our study and was not a part of our protocol. Patients with one of the following conditions or diseases were excluded; uncompensated heart failure, cardiac arrhythmias, unstable angina, end-stage renal disease, known bleeding disturbances, serious psychiatric disorders, serious eating disorders, cardiac pacemakers, intra-cardiac devices, cerebrovascular event or a myocardial infarction within the last six months. The inclusion period started February 2008 and ended February 2010. Initially, 148 patients accepted our invitation to participate in the study, 15 patients withdrew their consent before the study started, leaving a total of 133 patients in the present analysis. The study was approved by the regional ethics committee of the Southern Norway Regional Health Authority, and was performed in accordance with the Declaration of Helsinki \[[@B28]\]. Written informed consent was provided by all participants.

Variables
---------

The main outcome variable was arterial stiffness measured by PWV. The main explanatory variables were various measures and estimates of body composition, including anthropometric characteristics (WC, WHR, WHtR, BMI), data from bioelectrical impedance analysis (BIA) \[visceral fat area (cm2), fat mass (kg) and fat free mass (kg)\]. Potential confounders adjusted for were age, type 2 diabetes and arterial hypertension.

Data sources and measurements
-----------------------------

All participants underwent a medical examination performed by a physician and a trained nurse. Blood was collected by venipuncture following an overnight fast on the day of medical examination. Weight and height were measured with patients wearing light clothing and no shoes. BMI was calculated as weight in kilograms divided by the square of the height in meters. WC (cm) was measured midway between the 12th rib and the iliac crest. Blood pressure was measured after five minutes of rest using an electronic auscultatory blood pressure recorder with an appropriately sized cuff based on the measurement of arm circumference (Dinamap^®^, ProCare Series, G.E. Medical Systems) with the patient sitting in the upright position. Three measurements were recorded, and the average of the second and third measurement was recorded and used in the analysis. Bioelectrical impedance measures were collected using the Inbody 720, Body Composition Analyzer, Biospace Co. Ltd. Arterial hypertension was defined by either, a systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or the use of antihypertensive medication. Ischemic heart disease was defined as a history of stable coronary artery disease, percutaneous coronary intervention, coronary artery bypass graft surgery or myocardial infarction. The statistical analysis was performed using SPSS 16.0 (SPSS Inc., Chicago, IL).

Pulse wave velocity
-------------------

The measurement of PWV is generally accepted as the simplest, non-invasive, robust, and reproducible method to determine arterial stiffness and is considered to be the gold standard method \[[@B29]-[@B32]\]. \]. The Sphygmocor system (Artcor, Sidney, Australia) and a single high-fidelity applanation tonometer (Millar^®^) were used to measure PWV. Pulse waves were obtained sequentially from the carotid and femoral artery. The PWV was calculated from the transit time and the distance between these two arterial sites, determined in relation to the R-wave of the ECG, with patients lying in a horizontal position. Three complete sets of data were sampled and the average value was used as result. Bioelectrical impedance analysis was obtained using Inbody 720, Body Composition Analyzer, Biospace Co. Ltd. Each patient was undressed except for underwear, and placed in an upright position on the body composition analyzer. All jewelry and wristwatches were removed before the analyzer started recording. The InBody 720 uses the segmental BIA method in order to examine the body as five cylinders (four limbs and a trunk), and measures impedance in these parts separately. It also uses electrical current at multi-frequency (5, 50, 250, 500 and 1000 kHz) in order to directly measure the amount of extracellular and intracellular water. Homeostasis Model Assessment Insulin Resistance (HOMA- IR) was calculated as (\[fasting serum glucose (mmol/l) × fasting serum insulin (pmol/l)\]/135 \[[@B33]\]. Low-density lipoprotein cholesterol (LDL) concentrations were estimated by the Friedewald equation: LDLcholesterol = Total-cholesterol - HDL-cholesterol - (0.45 × triglycerides) \[[@B34]\]. S-LDL cholesterol was not calculated if S-triglycerides were \< 0.2 mmol/L or ≥ 5 mmol/L.

Laboratory analyses
-------------------

Analyses of serum glucose and blood lipids were performed using dry reagent slide technology on the Vitros FS 5.1 (Ortho-Clinical Diagnostics, New York, USA). Glycated hemoglobin (HbA1c) was analyzed using high performance liquid chromatography on Tosoh HLC-723 G7 (Tosoh Corporation, Tokyo, Japan). Sera for analysis of insulin were stored at - 20°C and analyzed within one week of blood sampling (Linco Research Inc, St. Charles, MO). Immunoturbidimetric method was used for determinations of apolipoprotein A-1 and apolipoprotein B (Modular, Roche Diagnostic GmbH).

Statistical methods
-------------------

Data are given as mean (SD) or n (%). Skewed data were ln-transformed to approximate normality before statistical analyses (HOMA-IR, S-f-glucose, S-f-insulin and S-triglycerides). Spearman\'s rank correlation was used to assess the bivariate association between the outcome and each of the exposure variables. Gender differences were analyzed using independent samples *t*-test for continuous data, whilst Fisher\'s exact tests were used for categorical data. The multiple linear regression analyses included the various measures of body composition, age, hypertension and type 2 diabetes as independent variables, and aortic PWV as dependent variable. Significant interactions between gender and BMI (p \< 0.001), WC (p = 0.019) and WHtR (p \< 0.001) made it appropriate to perform gender specific linear regression analyses. Semi-partial (part) correlation coefficients were squared in order to calculate the percentage of total variance in the dependent variable explained by a given independent variable.

Results
=======

A total of 133 morbidly obese persons (79 women), with a mean (SD) age of 43 (11) years, were included in the study. One hundred and six patients (59 women) had a BMI ≥ 40 kg/m^2^. Thirty one patients (24 women) were morbidly obese based on BMI alone (no comorbidity and BMI ≥ 40 kg/m^2^), whilst 27 patients (18 women) had a BMI between 35 and 40 kg/m^2^. Demographic characteristics, body composition and cardiovascular risk factors according to gender are shown in Table [1](#T1){ref-type="table"}. The male patients had a significantly higher prevalence of hypertension, type 2 diabetes and ischemic heart disease, as well as higher levels of fasting insulin, glucose and HbA1c than the female patients. Conversely, men had lower levels of total cholesterol, LDL-cholesterol and HDL-cholesterol than women. The male patients had higher PWV than the female patients, \[mean (SD) 9.1 (2.0) m/s vs. 8.1 (1.8) m/s, p = 0.003\].

###### 

Demographic characteristics, body composition, metabolic parameters and medications of 133 morbidly obese patients

  *Variable*                               *Total (n = 133)*   *Male (n = 54)*   *Female (n = 79)*   *P-value*
  ---------------------------------------- ------------------- ----------------- ------------------- -----------
  Age (years)                              43 (11)             45 (11)           41 (10)             0.107
  Hypertension\* (yes/no)                  90 (68%)            44 (81%)          46 (58%)            0.005
  Type 2 diabetes (yes/no)                 38 (29%)            25 (46%)          13 (17%)            \<0.001
  Ischemic heart disease (yes/no)          7 (5.3%)            6 (11.1%)         1 (1.3%)            0.018
  Current smoker (yes/no)                  20 (15%)            6 (11%)           14 (18%)            0.340
  Weight (kg)                              132 (22)            146 (23)          121 (16)            \<0.001
  *Various measures of body composition*                                                             
  Waist-to-hip ratio                       0.99 (0.10)         1.17 (0.07)       0.94 (0.07)         \<0.001
  Waist-to-height ratio                    75.3 (6.4)          79.2 (6.2)        74.4 (5.9)          \<0.001
  Waist circumference (cm)                 131 (14)            142 (12)          124 (10)            \<0.001
  BMI (kg/m^2^)                            44.5 (5.6)          46.1 (6.3)        43.5 (4.8)          0.008
  Fat mass (kg)                            63 (13)             66 (16)           61 (11)             0.055
  Fat free mass (kg)                       69 (13)             81 (10)           61 (7)              \<0.001
  Visceral fat area (cm^2^)                242 (48)            262 (55)          228 (37)            \<0.001
  *Metabolic variables*                                                                              
  apoB/apoA-1 ratio                        0.7 (0.2)           0.7 (0.2)         0.7 (0.2)           0.550
  Fasting insulin (pmol/L)                 100 (85)            125 (120)         87 (49)             0.048
  HOMA-IR†                                 4.6 (4.4)           6.1 (6.3)         3.5 (2.0)           0.002
  Fasting glucose (mmol/l)                 6.0 (2.2)           6.5 (2.7)         5.4 (1.1)           0.002
  B-HbA1c (%)                              6.2 (1.3)           6.5 (1.6)         5.7 (0.7)           0.001
  Pulse pressure (mmHg)                    62 (16)             63 (15)           61 (17)             0.471
  *Medication*                                                                                       
  β-blocker (yes/no)                       13 (10%)            8 (15%)           5 (6%)              0.134
  Calsium-channel blocker (yes/no)         17 (13%)            10 (19%)          7 (9%)              0.125
  Inhibitors of the RAA-system (yes/no)    37 (28%)            23 (43%)          14 (18%)            0.003
  Statins (yes/no)                         18 (14%)            13 (24%)          5 (6%)              0.008

Data are given as number (%) or mean (SD). \*Hypertension is defined by the patient receiving antihypertensive medication or having systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. † Homeostasis Model Assessment Insulin Resistance

Women
-----

In the female group, PWV was positively correlated with BMI, WC and WHtR (Figure [1](#F1){ref-type="fig"}). Table [2](#T2){ref-type="table"} shows that PWV was significantly correlated with visceral fat area, fasting glucose, HbA1c and the usage of β-blockers and calcium-channel blockers. Multiple linear regression analysis showed that BMI, WC, WHtR, visceral fat area and fat mass, but not WHR, were significantly associated with PWV after adjustment for age, hypertension and type 2 diabetes (table [3](#T3){ref-type="table"}). Based on part correlation BMI explained 14% of the variation in PWV, with WHtR explaining 12%, fat mass 8%, visceral fat area 8% and WC 6%.

![**Correlations between anthropometric measures and PWV**. The scatterplots show the relationship between anthropometric measures and PWV.](1471-2261-11-7-1){#F1}

###### 

Correlations between PWV, body composition, metabolic parameters and medications

  Independent variables                   Male (r)   Female (r)
  --------------------------------------- ---------- ------------
  Age                                     0.61†      0.52†
  Hypertension‡                           0.19       0.59†
  Type 2 diabetes (yes/no)                0.46†      0.18
  Visceral fat area (cm^2^)               -0.18      0.25\*
  Fat mass (kg)                           -0.26      0.06
  Fat free mass (kg)                      -0.15      -0.04
  apo-B/apoA-1 ratio                      -0.29      0.10
  Fasting insulin (mmol/L)                0.03       0.09
  HOMA IR§                                0.10       0.13
  Fasting glucose (mmol/L)                0.35\*     0.24\*
  HbA1c (%)                               0.27       0.31\*
  β-blocker (yes/no)                      0.12       0.39†
  Calsium-channel blocker (yes/no)        0.36\*     0.24\*
  Inhibitors of the RAA-system (yes/no)   0.29\*     0.14
  Statins (yes/no)                        0.39\*     0.22

\*p \< 0.05. †p \< 0.001. ‡ Hypertension is defined by the patient receiving antihypertensive medication or having systolic bloodpressure ≥ 140 mmHg or diastoic blood pressure ≥ 90 mmHg. §Homeostasis Model Assessment Insulin Resistance

###### 

Independent predictors of PWV after adjustment for age, hypertension and type 2 diabetes.

  Body composition            Β        95% CI            P         R Square
  --------------------------- -------- ----------------- --------- ----------
  *Female*                                                         
  Body mass index (kg/m^2^)   0.129    0.068 to 0.190    \<0.001   0.42
  Waist circumference (cm)    0.047    0.010 to 0.083    0.013     0.33
  Waist-to-hip ratio          -1.297   -6.109 to 3.522   0.594     0.28
  Waist-to-height ratio       0.108    0.052 to 0.164    \<0.001   0.40
  Visceral fat area (cm^2^)   0.014    0.005 to 0.024    0.004     0.35
  Fat mass (kg)               0.047    0.015 to 0.080    0.004     0.35
  Fat free mass (kg)          0.009    -0.046 to 0.065   0.736     0.27
  *Male*                                                           
  Body mass index (kg/m^2^)   -0.009   -0.083 to 0.065   0.806     0.47
  Waist circumference (cm)    0.014    -0.023 to 0.052   0.440     0.48
  Waist-to-hip ratio          1.933    -3.707 to 7.574   0.494     0.48
  Waist-to-height ratio       0.021    -0.053 to 0.094   0.575     0.48
  Visceral fat area (cm^2^)   0.003    -0.005 to 0.011   0.470     0.49
  Fat mass (kg)               0.005    -0.024 to 0.035   0.719     0.48
  Fat free mass (kg)          0.008    -0.033 to 0.050   0.693     0.48

Multiple linear regression analysis

Men
---

In the male group, PWV showed a significant negative correlation with BMI (Figure [1](#F1){ref-type="fig"}). The use of calcium-channel blockers, inhibitors of the RAA-system, statins and fasting glucose were positively correlated with PWV (Table [2](#T2){ref-type="table"}). BMI showed a negative association with age, r = -0.449, p = 0.001. Multiple linear regression analysis (Table [3](#T3){ref-type="table"}) did not demonstrate any significant association between measures of body composition and PWV after adjustment for age, hypertension and type 2 diabetes.

Discussion
==========

Key results
-----------

Our results indicate that measures of both general obesity and abdominal obesity are associated with PWV in morbidly obese women, but not in men. Thus, we could not confirm our initial hypothesis that abdominal obesity was a better predictor of aortic stiffness than general obesity.

Comparison with previous studies
--------------------------------

Our results support the findings of a previous study of normal weight and less obese European Caucasians which demonstrated that PWV increased with higher BMI in middle-aged and older women, but not in men \[[@B35]\]. Further, we are able to extend these findings to be valid in morbidly obese women. Partly in contrast with our findings, WC, but not BMI, was significantly associated with PWV in a cross-sectional study of middle aged, apparently healthy subjects \[[@B36]\]. In addition, no significant correlation between BMI and PWV was revealed in a recent prospective study of 29 morbidly obese subjects \[[@B37]\]. These discrepancies might have several explanations, including the low percentage of obese participants in the former study and the low number of participants in the latter. On the other hand, a study of less obese African-Americans and whites demonstrated that increased BMI, WC, and WHR were associated with higher PWV in both men and women \[[@B38]\]. Finally, baseline data from a longitudinal study of 50 (12 men) healthy obese patients (BMI \> 30 kg/m2) \[[@B39]\] showed that BMI and total fat mass, but not visceral fat mass, assessed by magnetic resonance imaging, were significantly associated with PWV in both genders. The latter is in opposition to our finding of a significant association between visceral fat area assessed by BIA and PWV in women. This difference in results might partly be explained by the higher degree of obesity in our study population and the larger proportion of metabolic disorders.

Gender differences
------------------

It is well known that for any given BMI, men have a larger amount of visceral adipose tissue and a higher risk of cardiovascular disease than women \[[@B13]\]. Our results are in agreement with this. Accordingly, our findings are discussed separately in men and women \[[@B40]\]. In the present study we observed an apparent lack of association between obesity and PWV among male patients in the multivariate analysis (Table [3](#T3){ref-type="table"}). This might partly be explained by a significantly higher prevalence of comorbidities and conditions known to increase PWV; such as hypertension, type 2 diabetes, ischemic heart disease and insulin resistance in our male population. Conversely, a weak negative correlation between BMI and PWV was shown in the univariate analysis of male subjects (Figure [1](#F1){ref-type="fig"}). This surprising finding might partly be explained by the coexistence of a significant negative correlation between age and BMI and the moderate positive correlation between age and PWV in our study. Finally, we cannot exclude the possibility that the number of male patients was too low to reveal a possible association between obesity and PWV.

Body Composition
----------------

The associations between various measures of overall and abdominal obesity and PWV in women were comparable in the present study. However, the amount of fat tissue associated with morbid obesity is likely to cause an accumulation of both visceral and subcutaneous fat. The effect of this can be a loss of superiority of one anthropometric measure of obesity to the other. Another area of concern is the relatively low reliability of the different anthropometric measures in this population\[[@B41]\]. This could imply that the correlations are underestimated and thus should be interpreted with caution. In addition, and in accordance with previous studies \[[@B9],[@B42]\], the anthropometric indexes taking height into account (BMI and WHtR) seemed to explain a larger part of the variation in PWV than WC, visceral fat area and fat mass. Accordingly, the usage of WC may underestimate the relative amount of abdominal fat in short subjects and overestimate it in tall subjects and consequently be misleading.

It is difficult to explain the lack of association between WHR and PWV in our study. This finding is in opposition to several other studies designed to explore the predictive value of various measures of obesity in relation to cardiovascular risk factors \[[@B43]\]. The detrimental effects of abdominal obesity may mitigate against the possible protective effect of subcutaneous fat located at the hip, despite only slightly increased WHR in morbidly obese patients. The low reliability of WHR as compared with WC in a morbidly obese population is also a factor that should be considered \[[@B41]\].

Other factors related to arterial stiffness
-------------------------------------------

In accordance with a recent study \[[@B44]\] demonstrating a significant association between fasting glucose and PWV in middle aged overweight and obese subjects, we found a significant positive correlation between fasting glucose and PWV in both men and women. In women, but not in men, we also found a positive correlation between HbA1c and PWV. Conversely, we could not demonstrate any association between HOMA-IR and PWV as shown in the previous study \[[@B44]\]. An elevated glucose level can cause a non-enzymatic glycation of matrix proteins and result in the accumulation of glycation end-products within the arterial wall and subsequent arterial stiffness \[[@B45]\].

Limitations and strengths
-------------------------

The major strengths of the present study are that arterial stiffness is a well validated risk marker of cardiovascular morbidity and mortality, as well as that PWV is considered to be the \"gold standard\" in assessing arterial stiffness. In terms of weaknesses, the cross-sectional design of the study necessarily implies that we cannot establish a cause-effect relationship. All but one participant, were white, and we are thus unable to generalize our results to non-white populations. It should also be noted that BIA is not considered to be a \"gold standard\" method. BIA has a tendency to underestimate the amount of fat tissue in morbidly obese patients when compared to hydrostatic weighing and dual-energy X-ray absorptiometry \[[@B46]-[@B48]\], although this is minimized by the usage of the segmental BIA method and multifrequency technology in the present study.

Conclusion
==========

Most measures of general and abdominal obesity were associated with arterial stiffness in morbidly obese women.
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